1Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue[M]. lyon, France: IARC, 2008 : 439.
2Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes [J]. Blood,1997,89(6):2 079-2 088.
3Verburgh E, Achten R, Louw VJ, et al. A new disease categorization of low-grade myelodysplastic syndromes based on the expression of cytopenia and dysplasia in one versus more than one lineage improves on the WHO classification[J]. Leukemia, 2007,21 (4) : 668-677.
5Garcia-Manero G, Shan J, Faderl S, et al. A prognostic score for patients with lower risk myelodysplastic syndrome[J]. Leukemia, 2008,22 (3) : 538-543.
6Nosslinger T, Reisner R, Koller E, et al. Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution[J]. Blood, 2001,98 (10) : 2 935-2 941.
2Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 1997, 89 : 2079-2088.
3Matsuda A, Germing U, Jinnai I, et al. Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes. Blood, 2005, 106: 2633-2640.
4Lee JJ, Kim HJ, Chung IJ, et al. Comparisons of prognostic scoring systems for myelodysplastic syndromes: a Korean multicenter study. Leuk Res, 1999, 23: 425-432.
5Kuendgen A, Matsuda A, Germing U. Differences in epidemiology of MDS between Western and Eastern countries: ethnic differences or environmental influence? Leuk Res, 2007, 31: 103-104.
6Chen B, Zhao WL, Jin J, et al. Clinical and cytogenetic features of 508 patients with myelodysplastic syndrome and comparison with those in Western countries. Leukemia, 2005, 19: 767-775.
7Muller-Berndorff H, Haas PS, Kunzmann R, et al. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: results of a single-center analysis. Ann Hematol, 2006, 85 : 502-513.
8Sole F, Espinet B, Sanz G, et al. Incidence, characterization and prognostic significance of chromosome abnormalities in 640 patients with primary myelodysplastic syndromes. Br J Haematol, 2000, 108 : 346-356.
9de Souza Fernandez T, Ornellas MH, Otero de Carvalho L, et al. Chromosomal alterations associated with evolution from myelodysplastic syndrome to acute myeloid leukemia. Leuk Res, 2000, 24 : 839-848.
10Breccia M, Mancini M, Nanni M, et al. Clinical features of prognostic significance in myelodysplastic patients with normal karyotype at high risk of transformation. Leuk Res, 2005, 29: 33-39.
6Ali Bay, Mehmet Keskin,Samil Hizli, et al. Thiamine-responsive megaloblastic anemia syndrome[J]. International Journal of He matology,2010,92 (3) :524-526.
7Cheson B D, Greenberg P L, Bennett J M, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia[J]. Blood, 2006, 108: 419.
8Cortelezzi A, Cattaneo C, Cristiani S, et al. Non-transferrin bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis[J]. HematolJ, 2000, 1 (3): 153.
